Biscayne Pharmaceuticals Presents Data At 2015 AES Meeting Confirming BIS-001 Is A Novel Mechanism, Highly Potent And Well-Tolerated Anti-Epileptic Drug

--Presentation at American Epilepsy Society Annual Meeting Shows Activity of Synthetically Produced BIS-001 Is Identical to the Original Natural Product Chinese Medicine That Has a Long History of Safe and Effective Use in CNS Disorders--

Dec 07, 2015, 08:00 ET from Biscayne Pharmaceuticals, Inc.

PHILADELPHIA and MIAMI BEACH, Fla., Dec. 7, 2015 /PRNewswire/ -- Biscayne Pharmaceuticals, Inc., reported that it is presenting data today on BIS-001 at the Annual Meeting of the American Epilepsy Society (AES).1 BIS-001 is a clinical-stage, highly potent and selective acetylcholinesterase (AChE) inhibitor that is a synthetic form of a traditional Chinese medicine. It has demonstrated superior efficacy in highly predictive models of difficult-to-treat epilepsy. In a Phase 1 study in adults with drug-resistant complex partial epilepsy, BIS-001 was safe and well-tolerated. Biscayne is initially developing BIS-001 for the treatment of adults with refractory focal epilepsy and children with Dravet syndrome, a devastating disorder characterized by frequent intractable seizures and cognitive impairment.

At the AES Annual Meeting, Biscayne is presenting data from a series of preclinical studies. They confirm that BIS-001 is a highly potent anti-epileptic drug, producing 100% control of seizures in a highly predictive induced seizure model run by the National Institutes of Health's Anticonvulsant Screening Program.

The studies also elucidate BIS-001's novel anti-epileptic mechanism of action. They show that BIS-001 is a powerful inhibitor of acetylcholinesterase, which in turn increases GABA levels that activate anti-excitatory pathways and result in improved seizure control. The studies also reinforce that BIS-001's potent seizure-protectant effect and clean safety profile are unique in the anti-cholinesterase class, highlighting the contrast with the narrow therapeutic window of marketed anti-cholinergic drugs such as Aricept® (donepezil), which makes them unsuitable as treatments for epilepsy.

BIS-001 is a fully synthetic version of the extracted Chinese medicine huperzine A. Another set of studies addressed whether Biscayne's proprietary manufacturing process for BIS-001 is scalable and whether it produces a drug that is equivalent to the natural product original. Data being presented at today's meeting confirm that BIS-001 can be efficiently produced using a scalable commercial process and importantly, that in a key predictive animal seizure model its therapeutic performance is virtually identical to extracted huperzine.

Epilepsy affects about three million people in the U.S. and over 50 million people worldwide. Many patients with epilepsy take multiple medications, yet as many as one-third are unable to control their seizures with current therapies.

Stephen Collins, MD, PhD, President and Chief Executive Officer of Biscayne, commented, "Epilepsy is a disabling disorder that affects millions of Americans, yet remains poorly treated in far too many. We believe that BIS-001 has the potential to provide an effective and safe new treatment option for many patients with refractory disease. In addition, huperzine A has shown promise in the treatment of dementia, so BIS-001 also has the potential to positively impact cognition in epilepsy patients, unlike most current treatments that adversely affect cognitive function. We look forward to initiating a Phase 1b clinical trial of BIS-001 in refractory epilepsy patients in 2016."

1 - The Development of BIS-001 for the Treatment of Seizure-Related Disorders, Johnstone JT, Schachter SC, Carlson H, Gersner R, Rotenberg A, Collins SD, American Epilepsy Society Annual Meeting, Poster No. 3.045, Session 3, December 7, 2015.

The American Epilepsy Society 69th Annual Meeting is being held in Philadelphia, PA, December 4-8, 2015.

About Biscayne Pharmaceuticals
Biscayne Pharmaceuticals is a clinical-stage biotechnology company developing drugs for difficult-to-treat conditions in two major disease areas: CNS disorders such as refractory epilepsy and drug-resistant cancer. Both programs are based on novel approaches with demonstrated potential for superior efficacy and safety. Lead CNS compound BIS-001 has shown striking efficacy in highly predictive models of difficult-to-treat epileptic conditions such as Complex Partial Seizures and Dravet syndrome. A Phase 1b/2a study is planned for 2016. Biscayne is also developing new cancer therapies that block growth hormone-releasing hormone (GHRH) receptors, a novel target that is present on many cancer cells. Biscayne plans to initiate IND-enabling studies for lead cancer agent BIS-1062 in the coming months. Biscayne's technology is licensed from Harvard University, the University of Miami, Yale University and the University of South Florida. Biscayne is headquartered in Miami, FL. For more information, visit biscaynepharmaceuticals.com

Contacts:


Biscayne Pharmaceuticals


Corporate:

Media: 

Jared Mendel

BLL Partners

(786) 502-4220

Barbara Lindheim

info@biscaynepharma.com

(212) 584-2276  


blindheim@bllbiopartners.com  

 

SOURCE Biscayne Pharmaceuticals, Inc.



RELATED LINKS

http://www.biscaynepharmaceuticals.com